|
EMA Nitrosamine Q&A Rev13 published
|
|
9
|
542
|
December 15, 2022
|
|
2 days seminar on nitrosamine and extractable & leachable
|
|
0
|
455
|
November 21, 2022
|
|
Selection of MDD in Finished product
|
|
1
|
499
|
October 5, 2022
|
|
AI for Nitroso-Duloxetine
|
|
5
|
1283
|
September 3, 2022
|
|
Exact Root causes for NDMA in Metformin & NDSRI's Impurities in Varenicline, Quinapril & Orphenadrine
|
|
4
|
812
|
July 7, 2022
|
|
Nitrosamines in Carbamazepine?
|
|
4
|
506
|
July 1, 2022
|
|
Api或起始物料中亚硝酸盐限度
|
|
1
|
429
|
June 29, 2022
|
|
Drug substance-related impurities (NDSRIs) in Drug product and Drug substances
|
|
7
|
2194
|
June 8, 2022
|
|
亚硝胺杂质分析方法验证的可接受标准
|
|
3
|
372
|
June 2, 2022
|
|
New webinar & Live Q&A May 24th by Naiffer Romero! Nitrosamine exchange – a USP’s knowledge community for all-things nitrosamine
|
|
0
|
296
|
April 22, 2022
|
|
Nitrosamine webinar
|
|
1
|
284
|
March 30, 2022
|
|
Azido Impurity Method LC-MS/MS
|
|
0
|
282
|
March 25, 2022
|
|
Mutagenic Impurities Strategies for Identification and Control - now published
|
|
9
|
405
|
March 2, 2022
|
|
Nitrosamine quantification by GC-MS & LC-MS
|
|
0
|
278
|
February 16, 2022
|
|
Most burning challenge for API manufacturers?
|
|
12
|
750
|
July 9, 2021
|